Oxford, United Kingdom

Patrick Eric Hanrahan

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Patrick Eric Hanrahan

Introduction

Patrick Eric Hanrahan is a notable inventor based in Oxford, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds aimed at treating metabolic disorders. His work is characterized by a focus on opioid receptor modulators, which have potential applications in addressing obesity and related health issues.

Latest Patents

Hanrahan holds a patent for "Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders." This patent describes compounds of formula (I) or pharmaceutically acceptable salts thereof, which function as opioid receptor modulators. Specifically, these compounds can act as mu-opioid receptor antagonists, neutral antagonists, or inverse agonists, making them useful in the treatment of metabolic disorders, including obesity. He has 1 patent to his name.

Career Highlights

Throughout his career, Hanrahan has been associated with Prosidion Limited, a company dedicated to advancing therapeutic solutions for metabolic diseases. His work at Prosidion has allowed him to explore innovative approaches to drug development, contributing to the company's mission of improving patient outcomes.

Collaborations

Hanrahan has collaborated with notable colleagues, including Jason Bloxham and Stuart Edward Bradley. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceutical research.

Conclusion

Patrick Eric Hanrahan's contributions to the field of metabolic disorder treatment through his innovative patent work exemplify the impact of dedicated inventors in advancing healthcare solutions. His ongoing efforts at Prosidion Limited continue to pave the way for future developments in this critical area of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…